Severe Ulcerative Colitis
AGA updates living guideline on pharmacological management of moderate to severe UC
In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.
Tulisokibart bests placebo, may yield ‘important clinical benefit’ via TL1A blockade in UC
Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to a new study that also incorporated a predictive biomarker for response.
VIDEO: Key aspects of treating, managing hospitalized IBD patients
NAPLES, Florida — In this video, Asad Ur Rahman, MD, a gastroenterologist at Cleveland Clinic Florida, spoke with Healio about key takeaways from his 2022 ACG/FGS Spring Symposium presentation on hospitalization in patients with severe IBD.
FDA approves Rinvoq for moderate to severe ulcerative colitis
Biopharmaceutical company AbbVie announced FDA approval for Rinvoq for the treatment of adults with moderately to severely active ulcerative colitis.
VIDEO: Rinvoq safe, effective as UC maintenance therapy
Remo Panaccione, MD, of the University of Calgary, reported Rinvoq safely and effectively maintained moderate-to-severe ulcerative colitis.